XBiotech (XBIT) Competitors

XBiotech (NASDAQ:XBIT) and Pyxis Oncology (NASDAQ:PYXS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations, institutional ownership, media sentiment and community ranking.

Does the media refer more to XBIT or PYXS?

In the previous week, Pyxis Oncology had 1 more articles in the media than XBiotech. MarketBeat recorded 2 mentions for Pyxis Oncology and 1 mentions for XBiotech. Pyxis Oncology's average media sentiment score of 0.33 beat XBiotech's score of 0.00 indicating that Pyxis Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
XBiotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pyxis Oncology	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Does the MarketBeat Community believe in XBIT or PYXS?

XBiotech received 299 more outperform votes than Pyxis Oncology when rated by MarketBeat users. However, 78.26% of users gave Pyxis Oncology an outperform vote while only 69.98% of users gave XBiotech an outperform vote.

Company	Underperform	Outperform
XBiotech	Outperform Votes 317 69.98%	Underperform Votes 136 30.02%
Pyxis Oncology	Outperform Votes 18 78.26%	Underperform Votes 5 21.74%

Which has stronger valuation and earnings, XBIT or PYXS?

XBiotech has higher revenue and earnings than Pyxis Oncology. XBiotech is trading at a lower price-to-earnings ratio than Pyxis Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XBiotech	$4.01M	60.06	-$24.56M	-$0.82	-9.65
Pyxis Oncology	N/A	N/A	-$73.79M	-$1.84	-2.46

Which has more volatility & risk, XBIT or PYXS?

XBiotech has a beta of 1.45, indicating that its share price is 45% more volatile than the S&P 500. Comparatively, Pyxis Oncology has a beta of 1.51, indicating that its share price is 51% more volatile than the S&P 500.

Is XBIT or PYXS more profitable?

XBiotech's return on equity of -10.82% beat Pyxis Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
XBiotech	N/A	-10.82%	-10.52%
Pyxis Oncology	N/A	-52.60%	-41.08%

Do analysts rate XBIT or PYXS?

Pyxis Oncology has a consensus price target of $8.50, indicating a potential upside of 87.64%. Given Pyxis Oncology's higher probable upside, analysts clearly believe Pyxis Oncology is more favorable than XBiotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XBiotech	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A
Pyxis Oncology	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	3.00

Do institutionals and insiders hold more shares of XBIT or PYXS?

55.7% of XBiotech shares are held by institutional investors. Comparatively, 39.1% of Pyxis Oncology shares are held by institutional investors. 28.4% of XBiotech shares are held by company insiders. Comparatively, 8.4% of Pyxis Oncology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

XBiotech beats Pyxis Oncology on 8 of the 15 factors compared between the two stocks.